In-House Versus Third-Party Service: Choosing a Support Model

The support model decision is usually made by default. A department that has always used a manufacturer’s service organisation continues to, and a department that has built a workshop continues to use it, and neither re-examines the choice because the equipment keeps working. The consequence appears when the equipment mix changes, when costs rise, or when the incumbent arrangement cannot support a new platform. Support is a capability decision rather than a purchasing decision, and this article compares the two models on what they actually require and what they transfer.

The question of which parts are used is a separate decision, and it is covered in our analysis of OEM versus third-party parts for used medical devices; this article concerns who performs the work and what that arrangement transfers, which is a different decision with its own cost, control and continuity consequences.

What Each Option Is Designed For

In-house service is designed to build capability inside the organisation. It optimises for control: the department decides priorities, keeps the records, and develops knowledge that accumulates over time. It requires people, documentation, test equipment, parts access and enough work to keep the capability current, and where those conditions hold, it is frequently the fastest and most economical model.

Third-party service is designed to supply capability without the organisation building it. It optimises for access: the department gains competence on platforms it could not otherwise support, and it converts a fixed capability cost into a variable one. It requires the organisation to specify the scope carefully, because what is supplied is defined by the agreement rather than by the department’s needs. The extractable summary is this: in-house service builds capability and control at a fixed cost, while third-party service supplies competence on demand and requires the scope to be specified precisely.

Neither model is a complete answer on its own in most organisations, and the useful framing is to decide what must be internal and what may be external. Work that determines priorities for clinical services, work that depends on knowledge of the department’s own environment, and work whose records must be immediately available are candidates for internal capability. Work that requires platform-specific competence the organisation cannot realistically build, and work whose demand is too irregular to justify a fixed cost, are candidates for external support.

How They Differ in Practice

The practical difference appears in how quickly work happens and in who decides. An in-house team can move a device to the front of the queue because a clinical service depends on it, and it can do so without renegotiating anything. A third-party arrangement delivers work according to an agreed priority, and while response terms can be written into an agreement, the provider’s ability to reorder its own workload is limited by its other commitments.

The second practical difference is knowledge. An in-house team accumulates understanding of its own fleet, its own failure patterns and its own environment, which is difficult to buy and valuable when diagnosing faults that do not follow the manual. A third-party provider brings breadth rather than depth, and that breadth is valuable when the equipment is unfamiliar. The most common arrangement in practice is a combination, with in-house capability covering routine work and third-party support for platforms or faults that the internal team cannot address.

A third practical difference is continuity. An in-house capability depends on individuals, and a department that loses its only technician on a platform loses the capability until somebody else is trained. A third-party arrangement depends on a relationship, and a provider that changes its own staffing or withdraws from a region creates a similar exposure. Neither model removes continuity risk; they place it in different locations, and identifying where it sits is part of the decision.

Cost and Lifecycle Differences

The two models have different cost shapes rather than different totals. In-house service costs are largely fixed: salaries, training, test equipment and parts stock are incurred whether or not the equipment fails. Third-party costs are largely variable and rise with the frequency and scope of work.

Compliance and Documentation Differences

Both models require records, and the difference lies in who holds them. In-house service keeps the service history, the configuration knowledge and the decisions locally, which makes acceptance, audit and resale straightforward. Third-party service produces records too, but they may sit with the provider, and the department’s ability to use them depends on access terms agreed at the start.

The obligation to keep equipment safe and available does not transfer with the arrangement. A department using a service provider remains responsible for the equipment’s condition and for the records that demonstrate it, which is why the access terms matter. Where the work depends on measurement, the traceability of the instruments used should be verifiable, and the ILAC accreditation directory allows a calibration provider’s status to be checked. The professional framework for servicing is covered by AAMI’s medical device servicing material, and independent guidance from organisations such as ECRI is a useful reference on maintenance practice.

The distinction between the two models is therefore narrower in documentation terms than in capability terms. Both produce records, both require competence, and both depend on the manufacturer’s documentation for the work performed. What differs is who holds the record and how quickly it can be produced, and that difference determines whether the organisation can genuinely change the arrangement later or is effectively committed to it.

Where the obligation to keep equipment available is expressed as a duty on the organisation, national workplace material such as the HSE health services guidance frames the position, and the device-side expectations that apply to equipment and its records are illustrated in one market by the MHRA guidance on regulating medical devices.

Where the Choice Is Genuinely Commercial

Once capability and access are understood, some decisions remain commercial. The first is the size of the fleet: an in-house team needs enough work to stay current, and a department with a small number of devices may not provide it. The second is the number of platforms: supporting several manufacturers in-house requires training across all of them, while a provider may already hold that competence.

The third is the variability of demand. An organisation whose equipment population is stable and whose failures are predictable can plan an in-house capability. One whose population changes frequently, or which supports equipment at several sites, may find that a provider gives it flexibility it could not build internally. The fourth is the cost of being wrong: where an in-house team cannot resolve a fault, the fallback is a provider anyway, and the practical question is how often that fallback is expected.

How to Trial the Decision Before Committing

The decision can be tested against a year of actual work. Take the last twelve months of maintenance activity, classify each event by platform and by whether it was routine or unexpected, and mark those the department could have handled internally. The result shows how much work an in-house capability would have covered, and how much would still have needed a provider.

Two further tests are useful. The first is a capability test: for the platforms that matter most, identify who would perform the work, what training they hold and what test equipment is required. The second is a records test: confirm where the service history would sit under each model and how quickly it could be produced. Both tests are quick, and both routinely change the preferred arrangement.

Which Buyer Profile Each Option Suits

The profiles below are descriptive, and many organisations will recognise a hybrid of several.

Buyers who want the wider context can start from the knowledge hub, see how equipment and its service position are described on the marketplace store, or use the service material in the industry hub. Our analysis of service contracts versus in-house biomedical support for used devices covers the contractual side of the same choice, and the device-side expectations that apply throughout are illustrated in one market by the MHRA guidance on regulating medical devices.

Part of the Medical Equipment Maintenance & Service guide.